Last updated on April 2020

PDD vs PAD to Treat Initially Diagnosed MM


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Multiple Myeloma
  • Age: Between 18 - 70 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Newly diagnosed and untreated multiple myeloma patients
  • Patients with age between 18 and 70 years
  • With a evaluable disease
  • ECOG score 2
  • NE1.010E9 /L, Plt5010E9 /L, Hb70 g/L
  • AST, ALT, ALP3ULN, serum BILULN
  • LVEF 50%
  • Not in pregnancy
  • Written informed consent are acquired

Exclusion Criteria:

  • Severe heart failure (NYHA grade II or higher)
  • Active and uncontrolled severe infection
  • HIV positive
  • Have accepted any other anti-tumor drug within 30 days before the first dose of doxorubicin hydrochloride iposome or doxorubicin
  • Grade 2 or higher peripheral neuropathy before treatment
  • Have suffered any other malignancy in past 5 years
  • Females in lactation
  • Other situations that investigators consider as contra-indication for this study

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.